Irritable Bowel Syndrome: Update From ACP 2015

Patients have wide misconceptions about the causes of IBS and fears about what it means for longevity. They are also eager for education on what they can eat, drugs that might help, and methods to cope.Based on information presented at the 2015 annual American College of Physicians Internal Medicine meeting, the short slide show above highlights:♦ Demographics of patients with IBS ♦ Foods recommended and not recommended, and why ♦ Current prescription medications that may help   References:1. Andrews EB, Eaton SC, Hollis KA, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005;22:935-942. doi:10.1111/j.1365-2036.2005.02671.x2. Halpert A, Dalton CB, Palsson O, et al. What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ). Am J Gastroenterol. 2007;102:1972-1982. Epub 2007 May 3.3. Choi YK1, Kraft N, Zimmerman B, et al. Fructose intolerance in IBS and utility of fructose-restricted diet. J Clin Gastroenterol. 2008;42:233-238. doi:10.1097/MCG.0b013e31802cbc2f.4. Lacy BE. Let’s get moving: a rational approach to diarrhea and constipation. Presented at: the American College of Physcians Internal Medicine Meeting; April 30-May 2, 2015; Boston.5. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702-1712.6. Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315-328. doi:10.1111/j.1365-2036.2008.03884.x. Epub 2008 Nov 8.